ProNoxis Overview

  • Year Founded
  • 2009

Year Founded

  • Status
  • Acquired/​Merged

  • Employees
  • 2

Employees

  • Latest Deal Type
  • M&A

ProNoxis General Information

Description

Developer of a small-molecule drug discovery platform designed to develop therapeutics for inflammatory, autoimmune, and infectious diseases. The company develops small-molecule agonists targeting the FPR/NOX2 (NADPH oxidase) pathway for preclinical drug discovery, enabling clients to develop therapies that modulate immune responses.

Contact Information

Ownership Status
Acquired/Merged
(Operating Subsidiary)
Financing Status
Formerly VC-backed
Corporate Office
  • Skogvaktaregatn 8
  • 461 33 Trollhattan
  • Sweden
+46 070-916
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Parent Company
Inexius
Vertical(s)
Corporate Office
  • Skogvaktaregatn 8
  • 461 33 Trollhattan
  • Sweden
+46 070-916

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

ProNoxis Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
7. Merger/Acquisition 01-Feb-2024 Completed Generating Revenue
6. Merger/Acquisition 26-Nov-2012 Completed Generating Revenue
5. Early Stage VC 17-Jun-2011 Completed Startup
4. Early Stage VC Completed Startup
3. Early Stage VC Completed Startup
2. Early Stage VC Completed Startup
1. Early Stage VC 01-Jan-2009 Completed Startup
To view ProNoxis’s complete valuation and funding history, request access »

ProNoxis Patents

ProNoxis Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
GB-201216381-D0 New compounds and medical uses Inactive 13-Sep-2012
GB-201208970-D0 New compounds and medical uses Inactive 22-May-2012
GB-201104872-D0 New compounds and medical uses Inactive 23-Mar-2011
GB-201104875-D0 New compounds and medical uses Inactive 23-Mar-2011
GB-201104600-D0 New compounds and medical uses Inactive 18-Mar-2011 A61K31/4741
To view ProNoxis’s complete patent history, request access »

ProNoxis Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

ProNoxis Former Investors (3)

Investor Name Investor Type Holding Investor Since Participating Rounds
KDventures Venture Capital Minority
Lund University Bioscience Venture Capital Minority
Redoxis VC-Backed Company Majority
To view ProNoxis’s complete investors history, request access »

ProNoxis FAQs

  • When was ProNoxis founded?

    ProNoxis was founded in 2009.

  • Where is ProNoxis headquartered?

    ProNoxis is headquartered in Trollhattan, Sweden.

  • What is the size of ProNoxis?

    ProNoxis has 2 total employees.

  • What industry is ProNoxis in?

    ProNoxis’s primary industry is Drug Discovery.

  • Is ProNoxis a private or public company?

    ProNoxis is a Private company.

  • What is ProNoxis’s current revenue?

    The current revenue for ProNoxis is .

  • How much funding has ProNoxis raised over time?

    ProNoxis has raised $637K.

  • Who are ProNoxis’s investors?

    KDventures, Lund University Bioscience, and Redoxis have invested in ProNoxis.

  • When was ProNoxis acquired?

    ProNoxis was acquired on 01-Feb-2024.

  • Who acquired ProNoxis?

    ProNoxis was acquired by Inexius.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process